Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment operations offers direct distribution in Canada and Puerto Rico; third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America; and EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.